This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $143,324,800 contract is for the procurement of adult influenza vaccines for the 2022-2023 flu season, with a period of performance from the award date of December 31, 2021 through February 28, 2023.
The contract does not utilize any set-asides and was awarded as a single award. Seqirus, through its Seqirus USA, Inc. division, will provide a range of influenza vaccine formulations and presentations, including multi-dose vials, pre-filled syringes, and specialized vaccines for different age groups. The vaccines will be delivered FOB destination to CDC distribution centers in Colorado and Tennessee, as well as potential deliveries to five CDC occupational health clinics. This IDC enables the CDC to place orders for vaccines as needed, providing flexibility in quantity and timing to support nationwide immunization efforts for military personnel, veterans, federal inmates, and the general public.
Generated 7/17/24, 9:12 AM